|Trade names||Epclusa, Sofosvel, Velpanat (all in combination with sofosbuvir)|
|Metabolism||Liver (CYP2B6, 2C8, 3A4)|
|Elimination half-life||15 hours|
|Excretion||Feces (94%), urine (0.4%)|
|Chemical and physical data|
|Molar mass||883.02 g·mol−1|
|3D model (JSmol)|
Velpatasvir is both an inhibitor and a substrate of the transporter proteins P-glycoprotein (Pgp), ABCG2, OATP1B1 and OATP1B3. It is partly degraded by the liver enzymes CYP2B6, CYP2C8 and CYP3A4. Substances that are transported or inactivated by these proteins, or interfere with them, can interact with velpatasvir. In studies, this has been found for the HIV combination efavirenz/emtricitabine/tenofovir, which reduces the area under the curve (AUC) of velpatasvir by about 50%, and the CYP3A4 and Pgp inducer rifampicin, which reduces its AUC by about 80%, rendering it likely ineffective. Digoxin is eliminated by Pgp; its AUC is increased by about 30% in combination with velpatasvir and sofosbuvir (although it is not clear which of the two is responsible for this effect).
Mechanism of action
Velpatasvir reaches highest blood plasma levels three hours after oral intake together with sofosbuvir. Plasma protein binding is over 99.5%. It is slowly metabolised by the liver enzymes CYP2B6, CYP2C8 and CYP3A4. While monohydroxylated and demethylated metabolites have been identified in human blood plasma and faeces, over 98% of the circulating substance is velpatasvir itself. 94% are excreted via the faeces, and only 0.4% via the urine. Biological half-life is about 15 hours.
- Velpatasvir/sofosbuvir, with more information about the drug combination
- Discovery and development of NS5A inhibitors
- "Epclusa (sofosbuvir and velpatasvir) Tablets, for Oral Use. Full Prescribing Information" (PDF). Gilead Sciences, Inc. Foster City, CA 94404. Retrieved 1 August 2016.
- FDA Approves Epclusa, Drugs.com
- Haberfeld, H, ed. (2016). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Epclusa 400 mg/100 mg Filmtabletten.